US3709898A
(en)
|
1971-02-09 |
1973-01-09 |
Upjohn Co |
Process for the production of triazolobenzodiazepines and intermediates
|
US3681343A
(en)
|
1971-05-11 |
1972-08-01 |
Upjohn Co |
6-phenyl-s-triazolo{8 4,3-a{9 {8 1,4{9 {0 benzodiazepines
|
US3812259A
(en)
|
1971-08-09 |
1974-05-21 |
Upjohn Co |
Animal feed and process
|
CH622019A5
(en)
|
1975-10-23 |
1981-03-13 |
Upjohn Co |
Process for the preparation of aminotriazolobenzodiazepines
|
FR2329668A1
(en)
|
1975-10-27 |
1977-05-27 |
Upjohn Co |
Sedative, tranquillising, antidepressant triazolo-benzodiazepines - prepn. from hydrazino-benzodiazepines
|
EP0087850A1
(en)
|
1982-01-04 |
1983-09-07 |
The Upjohn Company |
Benzodiazepines for anti-hypertensive use
|
DE3435973A1
(en)
|
1984-10-01 |
1986-04-10 |
Boehringer Ingelheim KG, 6507 Ingelheim |
PHARMACEUTICAL COMPOSITIONS CONTAINING DIAZEPINE WITH PAF-ANTAGONISTIC EFFECT
|
EP0230942B1
(en)
*
|
1986-01-21 |
1992-04-29 |
Boehringer Ingelheim Kg |
Thieno-1,4-diazepines
|
DD265405A5
(en)
*
|
1986-01-21 |
1989-03-01 |
Boehringer Ingelheim Kg,De |
NEW THIENO-1,4-DIAZEPINE
|
DE3724164A1
(en)
|
1986-07-25 |
1988-01-28 |
Boehringer Ingelheim Kg |
Novel 1,4-benzodiazepines, their preparation and use
|
WO1988009333A1
(en)
|
1987-05-28 |
1988-12-01 |
Yoshitomi Pharmaceutical Industries, Ltd. |
Thieno(triazolo)diazepine compound and medicinal application of the same
|
JPH0676326B2
(en)
|
1988-05-24 |
1994-09-28 |
吉富製薬株式会社 |
Cardiovascular drug
|
EP0368175A1
(en)
|
1988-11-06 |
1990-05-16 |
Boehringer Ingelheim Kg |
3S,7S-3-(Morpholinocarbonyl)-5-(2-chlorphenyl)-7,10-dimethyl-3,4-dihydro-2H,7H-cyclopenta[4,5]thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine.
|
EP0387613A1
(en)
*
|
1989-03-03 |
1990-09-19 |
Boehringer Ingelheim Kg |
Thienodiazepines
|
EP0407955A1
(en)
|
1989-07-12 |
1991-01-16 |
Boehringer Ingelheim Kg |
New hetrazepines acting as PAF antagonists, process for their production and their use as drugs
|
DE4010528A1
(en)
|
1990-04-02 |
1991-10-17 |
Boehringer Ingelheim Kg |
PRECARATIVE CHROMATOGRAPHIC SEPARATION METHOD FOR THE PRODUCTION OF ENANTIOMERALLY PURE HETRAZEPINE
|
JP2959591B2
(en)
*
|
1990-05-23 |
1999-10-06 |
吉富製薬株式会社 |
Thienotriazolodiazepine compounds
|
DE4107521A1
(en)
*
|
1991-03-08 |
1992-09-10 |
Boehringer Ingelheim Kg |
NEW ACYLAMINOSUBSTITUTED HETRAZEPINE
|
WO1993007129A1
(en)
|
1991-10-11 |
1993-04-15 |
Yoshitomi Pharmaceutical Industries, Ltd. |
Remedy for osteoporosis and diazepine compound
|
EP0661284A1
(en)
|
1992-09-18 |
1995-07-05 |
Yoshitomi Pharmaceutical Industries, Ltd. |
Thienodiazepine compound and medicinal use thereof
|
CA2159344A1
(en)
*
|
1993-03-30 |
1994-10-13 |
Minoru Moriwaki |
Cell adhesion inhibitor and thienotriazolodiazepine compound
|
JP3001979U
(en)
|
1994-03-14 |
1994-09-06 |
有限会社マルセ木工 |
Pole hanging
|
WO1995032963A1
(en)
|
1994-06-01 |
1995-12-07 |
Yoshitomi Pharmaceutical Industries, Ltd. |
Thienylazole compound and thienotriazolodiazepine compound
|
ATE203026T1
(en)
|
1995-01-06 |
2001-07-15 |
Hoffmann La Roche |
HYDROXYMETHYL-IMIDAZODIAZEPINES AND THEIR ESTERS
|
CN1101680C
(en)
|
1995-09-09 |
2003-02-19 |
弗·哈夫曼-拉罗切有限公司 |
Use of thienotriazolodiazepine to increase apolipoprotein A-I levels
|
US5893397A
(en)
|
1996-01-12 |
1999-04-13 |
Bioject Inc. |
Medication vial/syringe liquid-transfer apparatus
|
IL127516A0
(en)
|
1996-06-12 |
1999-10-28 |
Japan Tobacco Inc |
A cytokine production inhibitor
|
US5693641A
(en)
|
1996-08-16 |
1997-12-02 |
Berlex Laboratories Inc. |
Bicyclic pyrimidine derivatives and their use as anti-coagulants
|
KR100338144B1
(en)
|
1996-09-13 |
2002-05-24 |
가마쿠라 아키오 |
Tienotriazolodiazepine compounds and medicinal uses thereof
|
US6444664B1
(en)
|
1997-04-18 |
2002-09-03 |
Nederlandse Organisatie Voor Toegepast - Natuurweten Schappelijk Onderzoek (Tno) |
Method for controlling the plasma level of lipoproteins to treat alzheimeris disease
|
US5993412A
(en)
|
1997-05-19 |
1999-11-30 |
Bioject, Inc. |
Injection apparatus
|
JPH11228576A
(en)
|
1997-12-10 |
1999-08-24 |
Japan Tobacco Inc |
Apoptosis inhibitor
|
FR2779652B1
(en)
|
1998-06-15 |
2001-06-08 |
Sod Conseils Rech Applic |
USE OF DIAZEPINES FOR THE PREPARATION OF MEDICINES FOR THE TREATMENT OF CONDITIONS OR DISEASES IN WHICH ONE OF THE SOMATOSTATIN RECEPTORS IS INVOLVED
|
US7589167B2
(en)
|
2000-02-22 |
2009-09-15 |
J. David Gladstone Institutes |
ZA loops of bromodomains
|
JP4875277B2
(en)
|
2000-06-16 |
2012-02-15 |
田辺三菱製薬株式会社 |
Release pH range and / or rate controlling composition
|
WO2002002557A2
(en)
|
2000-06-30 |
2002-01-10 |
Neurogen Corporation |
2-phenylimidazo[1,2-a]pyridine derivatives: a new class of gaba brain receptor ligands
|
US20060142257A1
(en)
|
2001-01-19 |
2006-06-29 |
Eberhard Nieschlag |
Male contraceptive formulation comprising norethisterone
|
US6979682B2
(en)
|
2001-02-23 |
2005-12-27 |
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College |
Platelet-activating factor antagonist inhibition of angiogenesis and tumor growth induced by basic fibroblast
|
US6806272B2
(en)
|
2001-09-04 |
2004-10-19 |
Boehringer Ingelheim Pharma Kg |
Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
|
PL369740A1
(en)
|
2001-09-04 |
2005-05-02 |
Boehringer Ingelheim Pharma Gmbh & Co.Kg |
Novel dihydropteridinones, method for producing the same and the use thereof as medicaments
|
US20030216758A1
(en)
|
2001-12-28 |
2003-11-20 |
Angiotech Pharmaceuticals, Inc. |
Coated surgical patches
|
GB0206215D0
(en)
|
2002-03-15 |
2002-05-01 |
Novartis Ag |
Organic compounds
|
JP3096299U
(en)
|
2003-02-20 |
2003-09-12 |
宇輪工業股▲ふん▼有限公司 |
Foot type health device
|
US6861422B2
(en)
|
2003-02-26 |
2005-03-01 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
|
MXPA05009068A
(en)
|
2003-02-26 |
2005-10-19 |
Boehringer Ingelheim Pharma |
Dihydropteridinones, method for the production and use thereof in the form of drugs.
|
GB0305929D0
(en)
|
2003-03-14 |
2003-04-23 |
Novartis Ag |
Organic compounds
|
WO2005002526A2
(en)
|
2003-07-01 |
2005-01-13 |
President And Fellows Of Harvard College |
Method and compositions for treatment of viral infections
|
CN100584832C
(en)
|
2003-09-18 |
2010-01-27 |
诺瓦提斯公司 |
2,4-di (phenylamino) pyrimidines useful in the treatment of proliferative disorders
|
EP1528056A1
(en)
|
2003-10-29 |
2005-05-04 |
Academisch Ziekenhuis bij de Universiteit van Amsterdam |
Deoxynojirimycin analogues and their uses as glucosylceramidase inhibitors
|
US7759485B2
(en)
|
2004-08-14 |
2010-07-20 |
Boehringer Ingelheim International Gmbh |
Process for the manufacture of dihydropteridinones
|
US7728134B2
(en)
|
2004-08-14 |
2010-06-01 |
Boehringer Ingelheim International Gmbh |
Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
|
US20060058311A1
(en)
|
2004-08-14 |
2006-03-16 |
Boehringer Ingelheim International Gmbh |
Combinations for the treatment of diseases involving cell proliferation
|
US20060074088A1
(en)
|
2004-08-14 |
2006-04-06 |
Boehringer Ingelheim International Gmbh |
Dihydropteridinones for the treatment of cancer diseases
|
US20060035903A1
(en)
|
2004-08-14 |
2006-02-16 |
Boehringer Ingelheim International Gmbh |
Storage stable perfusion solution for dihydropteridinones
|
EP1784406A1
(en)
|
2004-08-27 |
2007-05-16 |
Boehringer Ingelheim International GmbH |
Dihydropteridinones, process for their preparation and their use as drugs
|
GB0419161D0
(en)
|
2004-08-27 |
2004-09-29 |
Novartis Ag |
Organic compounds
|
CN1759834B
(en)
|
2004-09-17 |
2010-06-23 |
中国医学科学院医药生物技术研究所 |
Application of berberine or associated with Simvastatin in preparing product for preventing or curing disease or symptom related to blood fat
|
US8044042B2
(en)
|
2005-05-30 |
2011-10-25 |
Mitsubishi Tanabe Pharma Corporation |
Thienotriazolodiazepine compound and medicinal use thereof
|
US20070203161A1
(en)
|
2006-02-24 |
2007-08-30 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
RU2485106C2
(en)
|
2005-06-08 |
2013-06-20 |
Райджел Фамэсьютикэлз, Инк. |
Compounds exhibiting jak-kinase activity (versions), method of treating jak-kinase mediated diseases, method of inhibiting jak-kinase activity (versions), pharmaceutical composition of said compounds
|
WO2007014838A1
(en)
|
2005-08-03 |
2007-02-08 |
Boehringer Ingelheim International Gmbh |
Dihydropteridinones in the treatment of respiratory diseases
|
EP1951684B1
(en)
|
2005-11-01 |
2016-07-13 |
TargeGen, Inc. |
Bi-aryl meta-pyrimidine inhibitors of kinases
|
US8604042B2
(en)
|
2005-11-01 |
2013-12-10 |
Targegen, Inc. |
Bi-aryl meta-pyrimidine inhibitors of kinases
|
US8133900B2
(en)
|
2005-11-01 |
2012-03-13 |
Targegen, Inc. |
Use of bi-aryl meta-pyrimidine inhibitors of kinases
|
AU2006330587B2
(en)
|
2005-12-23 |
2012-12-13 |
Glaxosmithkline Llc |
Azaindole inhibitors of aurora kinases
|
BRPI0706560A2
(en)
|
2006-01-17 |
2011-03-29 |
Hoffmann La Roche |
aryl-isoxazol-4-yl-imidazo [1,2-a] pyridine derivatives useful for the treatment of alzheimer's disease via gaba receptors
|
ZA200806871B
(en)
|
2006-02-14 |
2009-10-28 |
Vertex Pharma |
Dihydrodiazepines useful as inhibitors of protein kinases
|
KR20080095902A
(en)
|
2006-02-14 |
2008-10-29 |
버텍스 파마슈티칼스 인코포레이티드 |
Dihydrodiazepines useful as inhibitors of protein kinases
|
US20070218135A1
(en)
|
2006-03-14 |
2007-09-20 |
Glenmark Pharmaceuticals Limited |
Sustained release matrix pharmaceutical composition
|
US20090281191A1
(en)
|
2006-05-03 |
2009-11-12 |
Rangwala Shamina M |
Use of organic compounds
|
EP2029599A1
(en)
|
2006-05-19 |
2009-03-04 |
Astra Zeneca AB |
Dihydropteridine compounds as anti proliferative agents
|
WO2008009909A1
(en)
|
2006-07-17 |
2008-01-24 |
Astrazeneca Ab |
Pteridimones as modulators of polo-like kinase
|
MX337906B
(en)
|
2006-10-19 |
2016-03-28 |
Signal Pharm Llc |
Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors.
|
BRPI0718120A2
(en)
|
2006-10-25 |
2013-11-12 |
Chroma Therapeutics Ltd |
PTERIDINE DERIVATIVES AS POLE TYPE KINASE INHIBITORS USEFUL IN CANCER TREATMENT
|
US8338464B2
(en)
|
2006-11-30 |
2012-12-25 |
Albert Einstein College Of Medicine Of Yeshiva University |
Small molecule inhibitors of BCL6
|
CA2984226C
(en)
|
2006-12-26 |
2021-02-23 |
Lantheus Medical Imaging, Inc. |
Ligands for imaging cardiac innervation
|
JP2008156311A
(en)
|
2006-12-26 |
2008-07-10 |
Institute Of Physical & Chemical Research |
Brd2 bromodomain binder
|
ATE524472T1
(en)
|
2007-03-22 |
2011-09-15 |
Takeda Pharmaceutical |
SUBSTITUTED PYRIMIDODIAZEPINES SUBSTITUTED AS PLK1 INHIBITORS
|
WO2008137081A1
(en)
|
2007-05-02 |
2008-11-13 |
The Trustees Of Columbia University In The City Of New York |
Substituted ( 5, 6 ) -dihydronaphraalenyl compounds as reversible male contraceptives
|
KR20080107050A
(en)
|
2007-06-05 |
2008-12-10 |
울산대학교 산학협력단 |
Pharmaceutical composition for preventing or treating chronic graft-versus-host disease comprising anti-cd137 monoclonal antibody
|
EP2190849B1
(en)
|
2007-08-15 |
2013-11-20 |
Vertex Pharmceuticals Incorporated |
4-(9-(3,3-difluorocyclopentyl)-5,7,7-trimethyl-6-oxo-6,7,8,9-tetrahydro-5h-pyrimido[4,5-b[1,4]diazepin-2-ylamino)-3-methoxybenzamide derivatives as inhibitors of the human protein kinases plk1 to plk4 for the treatment of proliferative diseases
|
CN101917995A
(en)
|
2007-09-25 |
2010-12-15 |
武田药品工业株式会社 |
POLO sample inhibitors of kinases
|
RU2478100C2
(en)
|
2007-09-28 |
2013-03-27 |
Сайкласел Лимитед |
Pyrimidine derivatives used as protein kinase inhibitors
|
WO2009067547A1
(en)
|
2007-11-19 |
2009-05-28 |
Takeda Pharmaceutical Company Limited |
Polo-like kinase inhibitors
|
WO2009080638A2
(en)
|
2007-12-20 |
2009-07-02 |
Cellzome Limited |
Sulfamides as zap-70 inhibitors
|
EP2239264A4
(en)
|
2007-12-28 |
2012-01-11 |
Mitsubishi Tanabe Pharma Corp |
Antitumor agent
|
AU2009224804B2
(en)
|
2008-03-10 |
2013-12-05 |
Janssen Pharmaceutica Nv |
4-aryl-2-anilino-pyrimidines as PLK kinase inhibitors
|
EP2276747A1
(en)
|
2008-03-11 |
2011-01-26 |
Cellzome Limited |
Sulfonamides as zap-70 inhibitors
|
FR2928923B1
(en)
|
2008-03-21 |
2010-04-23 |
Sanofi Aventis |
POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYL-IMIDAZO-1,2-A! PYRIDINES, THEIR PREPARATION AND THEIR USE IN THERAPEUTICS
|
EP2112152A1
(en)
|
2008-04-22 |
2009-10-28 |
GPC Biotech AG |
Dihydropteridinones as Plk Inhibitors
|
WO2009153197A1
(en)
|
2008-06-18 |
2009-12-23 |
F. Hoffmann-La Roche Ag |
Halo-substituted pyrimidodiazepines as plkl inhibitors
|
WO2010015340A1
(en)
|
2008-08-06 |
2010-02-11 |
Bayer Schering Pharma Aktiengesellschaft |
Daa-pyridine as peripheral benzodiazepine receptor ligand for diagnostic imaging and pharmaceutical treatment
|
CN102216298B
(en)
|
2008-09-16 |
2014-04-16 |
Csir公司 |
Imidazopyridines and imidazopyrimidines as HIV-1 reverse transcriptase inhibitors
|
AU2009309691B2
(en)
|
2008-10-30 |
2015-04-02 |
Circomed Llc |
Thienotriazolodiazepine derivatives active on apo A
|
EP2356123B1
(en)
|
2008-11-13 |
2012-10-03 |
F.Hoffmann-La Roche Ag |
Spiro-5,6-dihydro-4h-2,3,5,10b-tetraaza-benzo[e]azulenes
|
JP5908728B2
(en)
|
2009-01-06 |
2016-04-26 |
ダナ ファーバー キャンサー インスティテュート インコーポレイテッド |
Pyrimido-diazepinone kinase skeletal compounds and methods of treating diseases
|
KR101779137B1
(en)
|
2009-01-23 |
2017-09-18 |
다케다 야쿠힌 고교 가부시키가이샤 |
Poly(adp-ribose)polymerase(parp) inhibitors
|
CN102020643A
(en)
|
2009-09-22 |
2011-04-20 |
上海恒瑞医药有限公司 |
dihydropteridine ketone derivative, and preparation method and medicinal application thereof
|
RU2012116525A
(en)
|
2009-09-25 |
2013-10-27 |
Вертекс Фармасьютикалз Инкорпорейтед |
METHODS FOR PRODUCING PERIMIDINE DERIVATIVES USED AS PROTEINKINASE INHIBITORS
|
GB0919431D0
(en)
|
2009-11-05 |
2009-12-23 |
Glaxosmithkline Llc |
Novel compounds
|
GB0919426D0
(en)
|
2009-11-05 |
2009-12-23 |
Glaxosmithkline Llc |
Novel compounds
|
GB0919423D0
(en)
|
2009-11-05 |
2009-12-23 |
Glaxosmithkline Llc |
Novel compounds
|
SI2496582T1
(en)
|
2009-11-05 |
2016-04-29 |
Glaxosmithkline Llc Corporation Service Company |
Benzodiazepine bromodomain inhibitor
|
CA2779355C
(en)
|
2009-11-05 |
2018-01-16 |
Glaxosmithkline Llc |
Benzodiazepine bromodomain inhibitor
|
GB0919434D0
(en)
|
2009-11-05 |
2009-12-23 |
Glaxosmithkline Llc |
Novel compounds
|
GB0919432D0
(en)
|
2009-11-05 |
2009-12-23 |
Glaxosmithkline Llc |
Use
|
EP2536725B1
(en)
|
2010-02-17 |
2015-10-28 |
Boehringer Ingelheim International GmbH |
Dihydropteridinones, method for production and use thereof
|
EP2571875A4
(en)
|
2010-05-14 |
2013-10-30 |
Dana Farber Cancer Inst Inc |
Male contraceptive compositions and methods of use
|
CN105582014B
(en)
|
2010-05-14 |
2019-06-14 |
达那-法伯癌症研究所 |
For treating the composition and method of leukaemia
|
JP5715241B2
(en)
*
|
2010-05-14 |
2015-05-07 |
ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド |
Compositions and methods for treating neoplasms, inflammatory diseases, and other disorders
|
CN103119160B
(en)
|
2010-05-14 |
2016-06-01 |
达那-法伯癌症研究所 |
For regulating compositions and the method for metabolism
|
MX362384B
(en)
|
2010-05-14 |
2019-01-15 |
Dana Farber Cancer Inst Inc |
Compositions and methods for treating neoplasia, inflammatory disease and other disorders.
|
WO2011161031A1
(en)
|
2010-06-22 |
2011-12-29 |
Glaxosmithkline Llc |
Benzotriazolodiazepine compounds inhibitors of bromodomains
|
US20120014979A1
(en)
|
2010-07-16 |
2012-01-19 |
Alexander Dent |
Use of bcl6 inhibitors for treating autoimmune diseases
|
US9358233B2
(en)
|
2010-11-29 |
2016-06-07 |
Boehringer Ingelheim International Gmbh |
Method for treating acute myeloid leukemia
|
AR084070A1
(en)
|
2010-12-02 |
2013-04-17 |
Constellation Pharmaceuticals Inc |
BROMODOMINIUM INHIBITORS AND USES OF THE SAME
|
US9249161B2
(en)
|
2010-12-02 |
2016-02-02 |
Constellation Pharmaceuticals, Inc. |
Bromodomain inhibitors and uses thereof
|
US20140066410A1
(en)
|
2011-02-23 |
2014-03-06 |
Icahn School Of Medicine At Mount Sinai |
Inhibitors of bromodomains as modulators of gene expression
|
AU2012223448B2
(en)
|
2011-02-28 |
2017-03-16 |
Epizyme, Inc. |
Substituted 6,5-fused bicyclic heteroaryl compounds
|
CN103619873A
(en)
|
2011-03-07 |
2014-03-05 |
泰莱托恩基金会 |
TFEB variants and uses thereof
|
GB201106799D0
(en)
|
2011-04-21 |
2011-06-01 |
Glaxosmithkline Llc |
Novel compounds
|
WO2013033269A1
(en)
|
2011-08-29 |
2013-03-07 |
Coferon, Inc. |
Bioorthogonal monomers capable of dimerizing and targeting bromodomains and methods of using same
|
WO2013033270A2
(en)
*
|
2011-08-29 |
2013-03-07 |
Coferon, Inc. |
Bromodomain ligands capable of dimerizing in an aqueous solution, and methods of using same
|
DE102011082013A1
(en)
|
2011-09-01 |
2013-03-07 |
Bayer Pharma AG |
6H-thieno [3,2-f] [1,2,4] triazolo [4,3-a] [1,4] diazepines
|
WO2013097052A1
(en)
|
2011-12-30 |
2013-07-04 |
Abbott Laboratories |
Bromodomain inhibitors
|
CN109529026A
(en)
|
2012-02-17 |
2019-03-29 |
安迅生物制药公司 |
For treating method, compound and the composition of influenza and parainfluenza patient
|
US20150133434A1
(en)
|
2012-03-28 |
2015-05-14 |
The J. David Gladstone Institutes |
Compositions and Methods for Reactivating Latent Immunodeficiency Virus
|
RU2635856C2
(en)
|
2012-08-08 |
2017-11-16 |
Новоматик Аг |
Method and system for tracking game activity
|
US20140107107A1
(en)
|
2012-09-28 |
2014-04-17 |
Oncoethix Sa |
Pharmaceutical formulation containing thienotriazolodiazepine compounds
|
WO2014071247A1
(en)
|
2012-11-02 |
2014-05-08 |
Dana-Farber Cancer Institute, Inc. |
Pyrrol-1 -yl benzoic acid derivates useful as myc inhibitors
|
CN105229002A
(en)
|
2012-12-20 |
2016-01-06 |
拜耳医药股份有限公司 |
Suppress the dihydro pyrido pyrazinones of BET albumen
|
US20140254659A1
(en)
|
2013-03-11 |
2014-09-11 |
Mediatek Inc. |
Video coding method using at least evaluated visual quality and related video coding apparatus
|
US8980879B2
(en)
|
2013-03-11 |
2015-03-17 |
Abbvie Inc. |
Bromodomain inhibitors
|
JP6419735B2
(en)
|
2013-03-12 |
2018-11-07 |
アッヴィ・インコーポレイテッド |
Tetracyclic bromodomain inhibitors
|
US9714946B2
(en)
|
2013-03-14 |
2017-07-25 |
Dana-Farber Cancer Institute, Inc. |
Bromodomain binding reagents and uses thereof
|
CN105611835A
(en)
|
2013-07-25 |
2016-05-25 |
达纳-法伯癌症研究所股份有限公司 |
Inhibitors of transcription factors and uses thereof
|
JP6663852B2
(en)
|
2013-09-19 |
2020-03-13 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
BH3 profiling method
|
WO2015081280A1
(en)
|
2013-11-26 |
2015-06-04 |
Coferon, Inc. |
Bromodomain ligands capable of dimerizing in an aqueous solution
|
WO2015081284A1
(en)
|
2013-11-26 |
2015-06-04 |
Coferon, Inc. |
Bivalent bromodomain ligands, and methods of using same
|
CA2932040A1
(en)
|
2013-12-10 |
2015-06-18 |
Abbvie Inc. |
Bromodomain inhibitors
|
US10793571B2
(en)
|
2014-01-31 |
2020-10-06 |
Dana-Farber Cancer Institute, Inc. |
Uses of diazepane derivatives
|
JP2017504653A
(en)
|
2014-01-31 |
2017-02-09 |
ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド |
Diaminopyrimidine benzenesulfone derivatives and uses thereof
|
KR20160111036A
(en)
|
2014-01-31 |
2016-09-23 |
다나-파버 캔서 인스티튜트 인크. |
Diazepane derivatives and uses thereof
|
US20160347750A1
(en)
|
2014-01-31 |
2016-12-01 |
Dana-Farber Cancer Institute, Inc. |
Dihydropteridinone derivatives and uses thereof
|
JP2017510561A
(en)
|
2014-02-26 |
2017-04-13 |
杏林製薬株式会社 |
Heterocyclic compounds
|
CN106456653A
(en)
|
2014-02-28 |
2017-02-22 |
腾沙治疗公司 |
Treatment of conditions associated with hyperinsulinaemia
|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
WO2016022902A1
(en)
|
2014-08-08 |
2016-02-11 |
Dana-Farber Cancer Institute, Inc. |
Diazepane derivatives and uses thereof
|
MX2017001757A
(en)
|
2014-08-08 |
2017-05-30 |
Dana Farber Cancer Inst Inc |
Dihydropteridinone derivatives and uses thereof.
|
KR20170101913A
(en)
|
2014-12-05 |
2017-09-06 |
에이치 리 모피트 캔서 센터 앤드 리서어치 인스티튜트 아이엔씨 |
Bromodomain inhibitor as adjuvant in cancer immunotherapy
|
EP3256470B1
(en)
*
|
2014-12-23 |
2023-07-26 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
US9694084B2
(en)
|
2014-12-23 |
2017-07-04 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
AU2016232705C1
(en)
|
2015-03-18 |
2021-06-17 |
Arvinas, Inc. |
Compounds and methods for the enhanced degradation of targeted proteins
|
EP3307728A4
(en)
|
2015-06-12 |
2019-07-17 |
Dana Farber Cancer Institute, Inc. |
Combination therapy of transcription inhibitors and kinase inhibitors
|
WO2017007612A1
(en)
|
2015-07-07 |
2017-01-12 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
EP3331905B1
(en)
|
2015-08-06 |
2022-10-05 |
Dana-Farber Cancer Institute, Inc. |
Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
|
US10772962B2
(en)
|
2015-08-19 |
2020-09-15 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of bromodomain-containing proteins
|
CA2992889A1
(en)
|
2015-09-04 |
2017-03-09 |
F. Hoffmann-La Roche Ag |
Phenoxymethyl derivatives
|
RS61803B1
(en)
|
2015-09-09 |
2021-06-30 |
Jubilant Biosys Ltd |
Tricyclic fused pyridin-2-one derivatives and their use as brd4 inhibitors
|
JP2018526421A
(en)
|
2015-09-11 |
2018-09-13 |
ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド |
Cyanothienotriazolodiazepines and their use
|
WO2017042100A1
(en)
|
2015-09-11 |
2017-03-16 |
Boehringer Ingelheim International Gmbh |
Pyrazolyl-substituted heteroaryls and their use as medicaments
|
BR112018004617A2
(en)
|
2015-09-11 |
2018-09-25 |
Dana Farber Cancer Inst Inc |
thienotriazoldiazepines acetamide and uses thereof
|
ES2943235T3
(en)
|
2015-11-25 |
2023-06-12 |
Gilead Apollo Llc |
Fungicidal compositions containing 2,4-dioxo-1,4-dihydrothieno[2,3-d]pyrimidine derivatives
|
WO2017091683A1
(en)
|
2015-11-25 |
2017-06-01 |
Visterra, Inc. |
Antibody molecules to april and uses thereof
|
PT3380479T
(en)
|
2015-11-25 |
2023-03-13 |
Gilead Apollo Llc |
Triazole acc inhibitors and uses thereof
|
CN108601788B
(en)
|
2015-11-25 |
2021-10-22 |
效应治疗股份有限公司 |
EIF 4A-inhibiting compounds and methods relating thereto
|
CN108349995B
(en)
|
2015-11-25 |
2021-08-03 |
吉利德阿波罗公司 |
Pyrazole ACC inhibitors and uses thereof
|
CN108290902B
(en)
|
2015-11-25 |
2021-08-31 |
吉利德阿波罗公司 |
Ester ACC inhibitors and uses thereof
|
KR20180081809A
(en)
|
2015-11-25 |
2018-07-17 |
다나-파버 캔서 인스티튜트 인크. |
Divalent bromo domain inhibitors and uses thereof
|
MX2018005222A
(en)
|
2015-12-01 |
2019-04-29 |
Nihon Nohyaku Co Ltd |
3h-pyrrolopyridine compound or n-oxide thereof, or salts thereof, agricultural and horticultural insecticide containing compound, and use thereof.
|
WO2017197046A1
(en)
|
2016-05-10 |
2017-11-16 |
C4 Therapeutics, Inc. |
C3-carbon linked glutarimide degronimers for target protein degradation
|
CN109790143A
(en)
|
2016-05-10 |
2019-05-21 |
C4医药公司 |
The C of amine connection for target protein degradation3Glutarimide degron body
|
WO2017201069A1
(en)
|
2016-05-18 |
2017-11-23 |
Biotheryx, Inc. |
Oxoindoline derivatives as protein function modulators
|
GB201608797D0
(en)
|
2016-05-19 |
2016-07-06 |
Ucb Biopharma Sprl |
Therapeutic use
|
WO2018064589A1
(en)
|
2016-09-29 |
2018-04-05 |
Dana-Farber Cancer Institute, Inc. |
Targeted protein degradation using a mutant e3 ubiquitin ligase
|